

**AWMSG ADVICE SUPERSEDED BY
NICE GUIDANCE (TA587)
NICE GUIDANCE ISSUED MAY 2019**

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

**Final Appraisal Recommendation
Advice No: 2116 – July 2016**

**Lenalidomide (Revlimid[®]▼) 2.5 mg, 5 mg, 7.5 mg, 10 mg,
15 mg, 20 mg, 25 mg hard capsules**

Submission by Celgene Ltd.

Recommendation of AWMSG

Lenalidomide (Revlimid[®]▼) is recommended as an option for restricted use within NHS Wales.

Lenalidomide (Revlimid[®]▼) in combination with low-dose dexamethasone should be restricted for use within its licensed indication for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant and are unsuitable for thalidomide-containing regimens.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.

Lenalidomide (Revlimid[®]▼) is not recommended for use within NHS Wales outside of this subpopulation.

Additional note(s):

- Please refer to the Summary of Product Characteristics for the full licensed indication.
- AWMSG considered that lenalidomide (Revlimid[®]▼) satisfied the AWMSG criteria for appraising orphan and ultra-orphan medicines and medicines developed specifically for rare diseases.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2614), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by the Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2116:
lenalidomide (Revlimid[®]) 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg hard capsules.
June 2016.